Other increases in the Q1 of 2023 when compared to the same period of 2022 included higher cost per headcount, Primarily in the R and D area, a $742,000 impairment charge for deferred offering costs And higher costs were legal fees and D and O insurance, mainly related to being a public company for the entirety of the Q1 of 2023. In the Q1 of 2023, stock compensation expense totaled 1,700,000 expense totaled $2,100,000 compared to $11,500,000 $1,400,000 in the Q1 of 2022, respectively. Operating loss for the Q1 of 2023 was $22,000,000 compared to an operating loss of $25,300,000 for the same period of 2022. Net loss for the Q1 of 2023 was $23,400,000 or $0.19 per share compared to a net loss of $17,600,000 $0.33 per share for the same period of 2022. Cash, cash equivalents and available for sale investments totaled $122,000,000 as of March 31, 2023 compared with 142 to have cash, cash equivalents and available for sale securities of between $65,000,000 $75,000,000 at the end of 2023.